Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

How Ozempic Maker Novo Nordisk Lost Its Shine

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed its fortunes.

Eshe Nelson
Author: Eshe Nelson

Written by

Eshe Nelson

in

Appointments and Executive Changes, Company Reports, Drugs (Pharmaceuticals), GLP-1 RAs (Drug), Ozempic (Drug), Regulation and Deregulation of Industry, Stocks and Bonds
←‘Fleetwood Mac’ at 50: A Marvel of Serendipity and Perfectionism
Cannonball with Wesley Morris: Beyoncé Isn’t Giving Up on America→

More posts

  • Gersh Signs Victoria Garrick Browne

  • Celtic sign Parma’s Sorensen, with more to come before deadline

  • Germany says Russia behind Leipzig airport drone attack

  • Trump says US position on Falklands ‘one of many’ under review

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube